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Background: Few studies have systematically addressed the role of epidural analgesia and caesarean delivery in
predicting the post-partum disease activity in women with Multiple Sclerosis (MS).
The objective of this study was to assess the impact of epidural analgesia (EA) and caesarean delivery (CD) on the
risk of post-partum relapses and disability in women with MS.
Methods: In the context of an Italian prospective study on the safety of immunomodulators in pregnancy, we
included pregnancies occurred between 2002 and 2008 in women with MS regularly followed-up in 21 Italian MS
centers. Data were gathered through a standardized, semi-structured interview, dealing with pregnancy outcomes,
breastfeeding, type of delivery (vaginal or caesarean) and EA. The risk of post-partum relapses and disability
progression (1 point on the Expanded Disability Status Sclae, EDSS, point, confirmed after six months) was assessed
through a logistic multivariate regression analysis.
Results: We collected data on 423 pregnancies in 415 women. Among these, 349 pregnancies resulted in full term
deliveries, with a post-partum follow-up of at least one year (mean follow-up period 5.5±3.1 years). One hundred
and fifty-five patients (44.4%) underwent CD and 65 (18.5%) EA. In the multivariate analysis neither CD, nor EA were
associated with a higher risk of post-partum relapses. Post-partum relapses were related to a higher EDSS score at
conception (OR=1.42; 95% CI 1.11-1.82; p=0.005), a higher number of relapses in the year before pregnancy
(OR=1.62; 95% CI 1.15-2.29; p=0.006) and during pregnancy (OR=3.07; 95% CI 1.40-6.72; p=0.005). Likewise, CD and
EA were not associated with disability progression on the EDSS after delivery. The only significant predictor of
disability progression was the occurrence of relapses in the year after delivery (disability progression in the year
after delivery: OR= 4.00; 95% CI 2.0-8.2; p<0.001; disability progression over the whole follow-up period: OR= 2.0;
95% CI 1.2-3.3; p=0.005).
Conclusions: Our findings, show no correlation between EA, CD and postpartum relapses and disability. Therefore
these procedures can safely be applied in MS patients. On the other hand, post-partum relapses are significantly
associated with increased disability, which calls for the need of preventive therapies after delivery.
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The influence of pregnancy in multiple sclerosis (MS) has
been extensively assessed. The large Pregnancy In Mul-
tiple Sclerosis (PRIMS) study reported that the rate of
relapses decreases during the pregnancy, increases during
the first trimester of postpartum, then returning to the
prepregnancy rate after delivery [1]. A pathophysiological
hypothesis for explaining the spontaneous remission of
MS during pregnancy is that pregnancy is associated with
a decrease in cellular immunity and an increase in
humoral immunity, and a shift away from Th1 to Th2
responses; on the contrary, delivery is associated with an
inversion of this balance and a shift from Th2 a Th1
responses [1].
Only three factors seem independently predictive of
an increase of relapses in the three-month post-partum
period: the number of relapses in the year before preg-
nancy, the number of relapses during pregnancy, and
the duration of MS [2]. The possible role of breastfeed-
ing is still under discussion. A recent study suggested a
protective role of exclusive breastfeeding on the risk of
post-partum relapses [3,4]. However, findings from lar-
ger studies PRIMS [1] and other more recent papers
[5–7] indicated that the reported association between
breastfeeding and a lower risk of relapses may simply
reflect a different patient behavior, since patients with a
less active disease are more likely to breastfeed.
Few studies have addressed the role of epidural analgesia
(EA) and caesareum delivery (CD) in predicting the post-
partum disease activity [1]. The PRIMS reported no correl-
ation between postpartum relapses and epidural analgesia
[2,8] although in that study this represented a secondary
outcome and no detailed analysis is provided.
In a previous multicentric, prospective study on a co-
hort of pregnant women followed-up in the main Italian
MS centers, we assessed the issues of disease-modifying
drugs (DMDs) safety [5] during pregnancy and the role
of breastfeeding [7]. The study also gathered detailed in-
formation on the use of epidural analgesia and type of
delivery as well as follow-up data on disease course after
delivery. In this further analysis of the same cohort, we
aimed at assessing the impact of EA and CD on the
post-partum relapse rate and disability, taking into ac-
count possible confounders.
Methods
Between 2002 and 2008, all pregnancies occurring in MS
patients diagnosed according to McDonald’s criteria [9]
and referred to the participating centers were identified
and tracked over the whole gestational period. The 21
participating sites represented the main Italian MS Cen-
ters located throughout the entire country. In the
present study, we included all the pregnancies resulting
in full term deliveries and having a post-partum follow-up duration of at least one year. All the patients were
regularly followed-up after the delivery every 6 months
and in the case of relapse. Clinical and therapeutic data
were gathered by the neurologist using a standardized
information form. After the delivery, the neurologist
administered a semi-structured interview to each patient
dealing with in utero exposures, pregnancy outcomes
and breastfeeding (see Additional file 1). Moreover, data
on type of delivery were categorized into vaginal, with
assistance (use of forceps or ventose) or without assist-
ance, or caesarean; information on epidural analgesia
included the reason (analgesia or anesthesia for caesar-
ean delivery). As for disease activity, date of onset and
number of relapses in the year prior to conception, dur-
ing pregnancy and in the year after delivery were
recorded. A relapse was defined as the appearance or re-
appearance of one or more symptoms attributable to
MS, accompanied by objective deterioration on neuro-
logical examination lasting at least 24 hours, in the ab-
sence of fever and preceded by neurological stability for
at least 30 days [9]. Disability was also recorded on the
Functional Systems and Expanded Disability Status Scale
(EDSS) [10] in case of relapses and over the follow-up
period. Disability progression was defined as a 1.5 point
EDSS increase for baseline score= 0; 1point EDSS in-
crease for baseline scores 1–5.5 and 0.5 point EDSS in-
crease for baseline scores >5.5. The EDSS increase had
to be confirmed at 6 and 12 months.
The study was approved by the ethic committee of the
University of Florence and a written consent was
obtained from all patients.
Statistical analysis
Group comparison was assessed with Pearson’s |2, Stu-
dent t and Mann–Whitney U tests, when appropriate.
An annualized relapse-rate was calculated for each tri-
mester in the year before, during and after pregnancy.
The relapse –rate in patients who underwent CD and
patients who did not, and patients who underwent EA
and patients who did not was compared using a 2
(Groups) × 11 (Time – 4 trimesters before conception, 3
trimesters during pregnancy, 4 trimesters after delivery)
mixed factorial design, with repeated measures on the
second factor. This allows to evaluate differences be-
tween the two groups (effect for group), within each
group over time (effect for time) and the interaction be-
tween group and time (effect for group x time).
Moreover, the patients were grouped in patients with
at least one relapse and in patients without relapses in
the year after delivery. The impact of CD and EA and
other possible predictors of post-partum relapses was
assessed through a logistic regression model. The follow-
ing covariates were entered in the model as possible
confounders: age at MS onset, age, disease duration and
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number of relapses in the year before pregnancy and
during pregnancy, exclusive breastfeeding. The sample
size was not estimated a-priori. However, the sample
included in our study would be able to detect a differ-
ence of 0.15 between two proportions with a significance
level of 0.05 and a power of approximately 0.80. All ana-
lyses were performed using the SPSS 18.0 running on
Windows (SPSS, Chicago, IL, USA).Results
During the study period, a total of 423 pregnancies were
tracked in 415 women. The last pregnancy included took
place on January 2008. Among these, 349 pregnancies
resulted in full term deliveries, with a post-partum fol-
low-up of at least one year (Figure 1). Table 1 shows the
main demographic and clinical characteristics of the
study cohort. No woman was lost to the follow-up. On
the whole, CD was applied in 155 patients (44.4%).
Sixty-five patients (18.5%) underwent EA (for analgesia
in 19, for CD in 46 subjects). There were no differences
between either patients with CD or patients with EA in
terms of the main demographic and clinical characteris-
tics. A trend was observed towards a higher proportion
of treatment with disease modifying drugs before preg-
nancy in patients with CD (Table 1).
The annualized relapse-rate in the year before concep-
tion, during pregnancy and after delivery is illustrated in
Figure 2. On the whole, relapse-rate significantly decreased
during pregnancy, particularly in the third trimester, and
increased in the post-partum, particularly in the first tri-
mester (effect for time F=6.07-3.25, p<0.001). There were
no differences in the mean relapse-rate and in the time-
dependent profile of the relapse-rate comparing patients
with and without caesarean delivery (effect for group
F=0.26, p=0.613; effect for group x time F=0.21, p=0.996),
as well as comparing patients with and without epidural
analgesia (effect for group F=0.29, p=0.589; effect for group
x time F=0.79, p=0.638).415 women
386 Live births 
37 pregnancies with 
follow-up < 1 year




Figure 1 Flow-chart of the pregnancies enrolled in the study.In the year after the delivery, 148 patients (42.4%)
experienced at least one relapse (Table 2). Patients with
relapses in the post-partum period had a higher EDSS
score at conception (1.72 ± 1.11 versus 1.37 ± 0.84:
p=0.001), experienced a higher number of relapses in
the year prior to pregnancy (0.56 ± 0.84 versus 0.25 ±
0.58: p<0.001) and during pregnancy (0.19 ± 0.46 versus
0.06 ± 0.23; p<0.001). Moreover, the proportion of
breastfeeding tended to be lower in patients with relapse
(29.1% versus 38.8%: p=0.066).
In the multivariate analysis, neither CD, nor EA were
associated with a higher risk of post-partum relapses.
Post-partum relapses were related to a higher EDSS at
conception (OR= 1.42; 95% CI 1.11-1.82; p=0.005), a
higher number of relapses in the year before pregnancy
(OR= 1.62; 95% CI 1.15-2.29; p=0.006) and during preg-
nancy (OR= 3.07; 95% CI 1.40-6.72; p=0.005). The predict-
ive role of a higher number of relapses in the year before
pregnancy and during pregnancy was also confirmed fo-
cusing the analysis on the relapse rate in the first trimester
post-partum (p< 0.035).
Disability progressed in 42 (12.0%) of patients in the
year after delivery and in 96 (27.5%) over the whole
follow-up period (mean follow-up period 5.5 ± 3.1
years). In both cases there was no association with CD
and EA. The only significant predictor of disability pro-
gression was the occurrence of relapses in the year after
delivery (disability progression in the year after delivery:
OR= 4.00; 95% CI 2.0-8.2; p<0.001; disability progression
over the whole follow-up period: OR= 2.0; 95% CI 1.2-
3.3; p=0.005).
Discussion
Approximately two third of patients with MS are women in
their childbearing-age and issues related to pregnancy are
of crucial importance in the decision making process and
counseling. In everyday clinical practice, neurologists often
are inquired by the patients on the impact of the pregnancy
on the disease course, the safety of disease modifying ther-
apies for both the mother and the child, and the safety and
feasibility of perinatal procedures, such as EA, CD and
breastfeeding. While the influence of pregnancy on MS
course is largely known [1], to date, there is accumulating
evidence on the safety of interferon and glatiramer acetate
exposure in terms of both maternal and fetal outcomes.
Conversely, relatively little is known about the role of EA
and CD as predictors of post-partum disease activity, and
available information comes mainly from old studies on
small samples [8]. An old study pointed to an increased risk
of relapses after the administration of bupivacaine greater
than 2,5 mg/ml [11]. However, this finding was not con-
firmed in more recent investigations [12]. The results from
our large cohort show that EA, performed in 18.5% of our
patients, did not significantly affect post partum relapses or
Table 1 Characteristics of the study sample
Total sample (#349) EA (#65) NEA (#284) p CD(#155) NCD (#194) p
Age at conception (mean, SD, years) 31.8 (4.7) 32.5 (4.7) 31.7 (4.7) 0.232 31.7 (4.7) 31.8 (4.7) 0.907
Age at onset (mean, SD, years) 24.7 (5.8) 24.6 (6.4) 24.8 (5.7) 0.860 24.5 (6.0) 24.8 (5.7) 0.550
Disease duration at conception (mean, SD, years) 7.1 (4.8) 7.8 (5.9) 6.97 (4.5) 0.279 7.27 (4.8) 7.0 (4.8) 0.689
EDSS at conception (mean, SD) 1.5 (1.0) 1.5 (0.97) 1.5 (0.98) 0.868 1.6 (1.0) 1.4 (0.92) 0.107
Treated with DMDs before pregnancy (#, %) 176 (50.4) 28 (43.1%) 147 (51.8) 0.226 87 (56.1) 89 (45.9) 0.057
Relapses in the year prior to pregnancy (mean, SD) 0.4 (0.7) 0.37 (0.6) 0.39 (0.7) 0.800 0.38 (0.73) 0.39 (0.7) 0.937
Relapses during pregnancy (mean, SD) 0.12 (0.4) 0.1 (0.3) 0.11 (0.3) 0.950 0.15 (0.42) 0.09 (0.29) 0.157
Relapses in the year after the delivery (mean, SD) 0.45 (0.7) 0.35 (0.57) 0.48 (0.76) 0.130 0.47 (0.8) 0.44 (0.67) 0.677
Exclusive breastfeeding (#,%) 162 (46.4) 19 (29.2) 99 (34.9) 0.370 47 (30.3) 71 (36.6) 0.316
EA: epidural analgesia.
NEA: Not epidural analgesia.
CD: caesarean delivery.
NCD: not caesarean delivery.
SD: Standard Deviation.
EDSS: Expanded Disability Status Scale.


















Figure 2 Annualized relapse-rate before, during and after pregnancy in patients who underwent CD (left) and patients who underwent
EA (right). CD: Caesarean Delivery, EA: Epidural analgesia.
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ciated to a worsening of the MS after the delivery. As
observed in the PRIMS study, the risk of post-partum
relapses and disability progression was predicted by higher
pre-pregnancy and gestational disease activity.
As for CD, it has to be noted that in our sample, the
proportion of caesarean deliveries was in the upperTable 2 Characteristics of patients with and without post-par
Relapsin
Age at conception (mean, SD, years) 31.5
Age at onset (mean, SD, years) 24.8
Disease duration at conception (mean, SD, years) 6.9
EDSS at conception (mean, SD) 1.7
Treated with DMDs prior to pregnancy (#, %) 70 (
Relapses in the year prior to pregnancy (mean, SD) 0.56
Relapses during pregnancy (mean, SD) 0.19
EA (#, %) 24 (
CD (#, %) 62 (
Breastfeeding (#, %) 43 (2
SD: Standard Deviation.
EDSS: Expanded Disability Status Scale.
DMDs: Disease Modifying Drugs.
EA: Epidural Analgesia.
CD: Caesarean Delivery.limit of the estimates comparing with the general Italian
population [5].
In the interpretation of the study results, some pos-
sible limitations should be taken into account. Although
the 21 participating sites represented the largest Italian
MS centers and covered the whole territory, the study
population may not be entirely representative of thetum relapses
g (#148) Non relapsing (#201) p
(5.0) 32.1 (4.5) 0.241
(6.1) 24.7 (5.7) 0.930
(5.0) 7.4 (4.8) 0.355
(1.1) 1.4 (0.8) 0.001
47.3) 106 (52.7) 0.315
(0.84) 0.25 (0.59) <0.001
(0.46) 0.06 (0.23) <0.001
16.2) 40 (19.9) 0.371
41.9) 93 (46.3) 0.416
9.1%) 78 (38.8%) 0.066
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may be affected to some extent by local differences in
overall use of EA and CD across the country. Moreover,
there is no information on the type and dosages of
anesthetic used for EA.
Conclusions
On the whole, our study provides data useful for patient
counseling, showing that EA and CD can be considered
safe in female MS patients and adopted when appropri-
ate, without any risk of increased disease activity.
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